ResMed, Inspire Medical fall after Lilly's weight-loss drug succeeds in sleep apnea trials

** Shares of ResMed RMD, Inspire Medical INSP fall premarket after Eli Lilly's LLY weight-loss drug succeeds in trials testing it in sleep apnea patients

** ResMed shares down 6.6% to 172.60, Inspire Medical stock falls 7.7% to $204.50

** Lilly's weight-loss drug helped cut frequency of irregular breathing in patients with obstructive sleep apnea by as much as 63% on average across two late-stage trials

** LLY shares up 1.2% to $755.72

** ResMed and Inspire Medical make medical devices used to treat sleep apnea, a potentially serious sleep disorder in which breathing repeatedly stops and starts

** As of last close, RMD shares up 7.5% YTD, INSP up ~9%